Common Stock, $0.01 par value
- Symbol
- ZBH
- Exchange
- NYSE
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Zimmer Biomet Holdings, Inc.
ZBHNYSEEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 5, 2026, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report.…
Press release in this filing
Zimmer Biomet Announces Second Quarter 2026 Financial Results →Company context
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
Current securities
Registered securities in this filing
ZIMMER BIOMET HOLDINGS, INC. · 8-K · Filed 2026-08-05
2.425% Notes due 2026
- Symbol
- ZBH 26
- Exchange
- NYSE
- Classification
- DEBT
1.164% Notes due 2027
- Symbol
- ZBH 27
- Exchange
- NYSE
- Classification
- DEBT
3.518% Notes due 2032
- Symbol
- ZBH 32
- Exchange
- NYSE
- Classification
- DEBT
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On August 5, 2026, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report.
The information contained in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” with the Securities and Exchange Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
Filed exhibits (1)
EX-99.1 2 zbh-ex99_1.htm EX-99.1 EX-99.1 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Troy Kirkpatrick David DeMartino 614-284-1926 646-531-6115 troy.kirkpatrick@zimmerbiomet.com david.demartino@zimmerbiomet.com Kirsten Fallon Zach Weiner 781-779-5561 908-591-6955 kirsten.fallon@zimmerbiomet.com zach.weiner@zimmerbiomet.com Zimmer Biomet Announces Second Quarter 2026 Financial Results • Second quarter net sales of $2.177 billion increased 4.8% on a reported basis, 4.7% on a constant currency1 basis and 4.0% on an organic constant currency1 basis • Second quarter diluted earnings per share were $1.03, an increase of 33.8%; adjusted1 diluted earnings per share were $2.07, consistent with the prior year period • Company updates full-year 2026 financial guidance (WARSAW, IN) August 5, 2026 - Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2026. The Company reported second quarter net sales of $2.177 billion,…
Open exhibit ↗